Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant health concern worldwide, particularly in developing countries. Recent advancements in diagnostic methods and therapeutic strategies necessitate an updated approach to manage this condition effectively.
Traditional diagnostic methods, such as blood culture, have limitations in sensitivity and specificity. Recent developments now favor molecular diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These offer superior sensitivity and can detect the pathogen even in low concentrations, thus improving diagnostic accuracy.
The rise of antimicrobial resistance in Salmonella Typhi and Paratyphi has complicated the management of enteric fever. However, newer antibiotics such as azithromycin and third-generation cephalosporins have shown promising results. Moreover, the WHO now recommends a regimen of gatifloxacin or azithromycin, particularly in regions with high antimicrobial resistance.
Vaccination remains a cornerstone in the prevention of enteric fever. The Ty21a and Vi polysaccharide vaccines have been in use for some time. However, the recently introduced typhoid conjugate vaccine (TCV) has shown superior efficacy and duration of protection. The WHO now recommends TCV for routine use in typhoid-endemic areas.
Emerging technologies such as digital health tools can play a pivotal role in managing enteric fever. Mobile health applications can aid in early detection, while telemedicine can ensure timely treatment in resource-limited settings. Additionally, data analytics can help track disease trends and antimicrobial resistance patterns, aiding in public health planning.
Given the evolving landscape of enteric fever diagnosis and management, it is crucial for clinicians to stay updated with the latest advancements. Embracing molecular diagnostics, newer antibiotics, effective vaccines, and digital health tools can significantly improve patient outcomes and curb the spread of this disease.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation